Agomab Therapeutics(AGMB)
Belgium - AntwerpenBiotechnology
Focus: Agomab Therapeutics is a Belgium-based biotechnology company specializing in agonistic monoclonal antibody molecules, currently in early-stage clinical development with a pipeline focused on immunology-related indications. As a publicly traded company, it operates at the pre-revenue biotech scale with limited commercial infrastructure.
Profile data last refreshed 8h ago · AI intelligence enriched 2w ago
Funding Stage
PUBLIC
Open Jobs
3+2 this month
Stable — net +2 jobs in 30d
2 added, 0 removed. Backfill posture.
Should You Work at Agomab Therapeutics?
AI assessmentSuitable for scientists seeking deep platform expertise and early-stage impact, but limited job availability and pre-revenue status pose near-term career continuity risk.
Why Work Here
- Proprietary agonistic mAb platform represents differentiated science with potential to address underserved immunology markets.
- Public company status provides salary stability and potential equity upside, reducing typical biotech financial risk.
Data completeness
4/9 — Basic
Company HealthSolid
Pipeline
Early-stage
4 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
ORG-129
Healthy VolunteersClinical Trials (1)
NCT04933565First in Human Study of ORG-129 in Healthy Volunteers
Phase 1Help build intelligence for Agomab Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.